



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION



Acid Ceramidase (human, recombinant)



Item No. 31491

Overview and Properties

Synonyms:	AC, ACDase, Acid CDase, Acylsphingosine Deacylase, ASAH, N-Acylethanolamine Hydrolase, N-Acylsphingosine, N-Acylsphingosine Amidohydrolase, PHP32
Source:	Active recombinant human N-terminal His-tagged AC expressed in insect cells
Amino Acids:	22-395
Uniprot No.:	Q13510
Molecular Weight:	44 kDa
Storage:	-80°C (as supplied)
Stability:	≥1 year
Purity:	≥65% estimated by SDS-PAGE
Supplied in:	1x PBS, pH 7.2, 0.2% Triton X-100, 20% glycerol
Protein Concentration:	<i>batch specific</i> mg/ml

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



ASAHI-1 Fluorescence Activity Assay. Acid Ceramidase activity was monitored by fluorescence spectroscopy. An acid ceramidase-specific substrate is cleaved generating a fluorescent signal with $\lambda_{Ex} = 355$ nm and $\lambda_{Em} = 460$ nm.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/03/2025

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Acid ceramidase (AC) is a hydrolase and member of the N-terminal nucleophile superfamily of hydrolases.^{1,2} It is initially expressed as a proenzyme, which undergoes autocleavage at the peptide bond between threonine 142 and cysteine 143 to produce the active enzyme.³ AC is composed of an α -subunit domain and a β -subunit domain linked by a disulfide bond.^{1,3} It is ubiquitously expressed and located in the lysosome.³ AC is involved in sphingolipid degradation and hydrolyzes ceramides into sphingolipids and free fatty acids.⁴ Mutations in *ASAH1*, the gene encoding AC, are found in patients with Farber disease or spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME).^{2,5} Cayman's Acid Ceramidase (human, recombinant) protein can be used for enzyme activity assay, ELISA, and Western blot (WB) applications.

References

1. Gebai, A., Gorelik, A., Li, Z., *et al.* Structural basis for the activation of acid ceramidase. *Nat. Commun.* **9**(1), 1621 (2018).
2. Momoi, T., Ben-Yoseph, Y., and Nadler, H.L. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls. *Biochem. J.* **205**(2), 419-425 (1982).
3. Ferlinz, K., Kopal, G., Bernardo, K., *et al.* Human acid ceramidase. Processing, glycosylation, and lysosomal targeting. *J. Biol. Chem.* **276**(38), 35352-35360 (2001).
4. Zeidan, Y.H., Jenkins, R.W., Korman, J.B., *et al.* Molecular targeting of acid ceramidase: Implications to cancer therapy. *Curr. Drug Targets* **9**(8), 653-661 (2008).
5. Yu, F.P.S., Amintas, S., Levade, T., *et al.* Acid ceramidase deficiency: Farber disease and SMA-PME. *Orphanet J. Rare Dis.* **13**(1), 121 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM